Hims — the next gen telehealth startup that made waves by taking the eye contact out of erectile dysfunction treatment. Of ...

Copycat versions of Eli Lilly's diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They're ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic ...

The United States has led the world in pharmaceutical innovation for decades by developing drugs that combat cancer, heart ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

The future of American drug innovation is threatened by U.S. regulations that permit knockoff versions of new drugs to be ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

This week was supposed to mark the end of compounding pharmacies making copycat versions of Eli Lilly's weight-loss drug Zepbound and its diabetes drug Mounjaro. Online, it doesn't look like much ...